Starling Oncology, Inc. (STLNW) stock
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Starling Oncology, Inc. grew revenue 38.4% to $587.24M over the twelve months to Jun 30, 2026. Free cash flow was -$3.29M. At the latest close the market valued the company at $665.51M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $665.51M
- P/E ratio
- –
- Price to sales
- 1.13
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -0.49%
Fundamentals
- Revenue
- $587.24M
- Net income
- -$36.29M
- EPS, diluted
- -$0.30
- Free cash flow
- -$3.29M
- Book value per share
- -$0.24
- Diluted shares
- 103M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $0.02
- Open
- $0.03
- Day's range
- $0.03 – $0.03
- Volume
- 5,006
- Average volume (20 days)
- 5,185
- Beta (5 years)
- 1.60
- 52-week range
- $2.32 – $7.13
- RSI (14 days)
- 49.5
- Volatility (1 year)
- 80.0%
- Relative volume
- 0.91×
- WACC
- 12.4%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | STLNW | S&P 500 | Difference | STLNW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -47.7% | -0.9% | −46.8 pts | ||
| 3 months | -49.0% | +2.1% | −51.1 pts | ||
| Year to date | -78.8% | +11.7% | −90.5 pts | ||
| 1 year | -90.2% | +12.4% | −102.5 pts | ||
| 3 years | -81.8% | +88.6% | −170.4 pts | -43.3% | +23.5% |
| 5 years | -98.5% | +75.9% | −174.4 pts | -56.8% | +12.0% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Starling Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Results
About Starling Oncology
Services-Offices & Clinics of Doctors of Medicine
The Oncology Institute, Inc. delivers outpatient medical and radiation oncology care alongside specialty pharmacy and clinical research services. The company provides treatments such as in-house infusion, radiation therapy, and blood product transfusions, operating through patient services, pharmacy distribution, and clinical trial management. It delivers care under fee-for-service arrangements and value-based risk contracts, including capitation and full delegation models where it assumes administrative functions such as utilization management and claims processing. Its customer base includes commercial and government healthcare payors, Medicare Advantage plans, Medicaid, managed care organizations, and adult cancer patients.
Company profile, executives and historyStarling Oncology stock: common questions
What is Starling Oncology's stock price?
STLNW closed at $0.03 on Oct 30, 2026, up 10.87% on the day. Over the past 52 weeks it traded between $2.32 and $7.13.
What is Starling Oncology's market cap?
Starling Oncology was worth $665.51M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is STLNW's P/E ratio?
Starling Oncology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.30), so it has no meaningful P/E ratio.
How much revenue does Starling Oncology make?
Starling Oncology reported revenue of $587.24M for the twelve months to Jun 30, 2026, up 38.4% from a year earlier.
Does Starling Oncology pay a dividend?
No. Starling Oncology has not paid a cash dividend over the last twelve months.
When does Starling Oncology report earnings next?
Starling Oncology is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has STLNW stock performed over the past year?
Including dividends, STLNW returned -90.2% over the past year, against +12.4% for the S&P 500.
Who are Starling Oncology's competitors?
Companies most similar to Starling Oncology by business, industry and size include CCM, SBC, LFMD, TDOC, AUNA.